← Back to search
7k15

Crystal structure of the Human Leukotriene B4 Receptor 1 in Complex with Selective Antagonist MK-D-046

Method: X-RAY DIFFRACTION Dmax: 112.8 Å Quality: REASONABLE
▼

1. Protein Identity and Related Structures Protein Identity & Related Structures

Leukotriene B4 receptor 1,Flavodoxin,Leukotriene B4 receptor 1

Homo sapiens

UniProt P00323

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Insufficient information Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count Chain A； UniProt 2–148 Not recorded VRJ N-(tert-butylsulfonyl)-4-fluoro-2-{(3S,4R)-4-hydroxy-3-[(pyridin-2-yl)methyl]-3,4-dihydro-2H-1-benzopyran-7-yl}benzamide × 1 NA SODIUM ION × 1 FMN FLAVIN MONONUCLEOTIDE × 1 OLA OLEIC ACID × 1 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2 1PE PENTAETHYLENE GLYCOL × 1 2PE NONAETHYLENE GLYCOL × 1 P6G HEXAETHYLENE GLYCOL × 1 X-RAY DIFFRACTION X-ray crystallization conditions：LIPIDIC CUBIC PHASE；pH 5.8；293 K；sodium citrate tribasic dihydrate pH 5.8, sodium acetate trihydrate, benzamidine hydrochloride, PEG-400, MK-D-046, DMSO Resolution 2.88 Å R-free 0.261

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 7K15 Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
1AKQ D95A OXIDIZED FLAVODOXIN MUTANT FROM D. VULGARIS Deposited 1997-03-27 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：D95A FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7；PROTEIN WAS CRYSTALLIZED FROM 60-70% A.S., 100MM TRIS-HCL, PH=7.0.
Resolution 1.90 Å R-free 0.240
1AKR G61A OXIDIZED FLAVODOXIN MUTANT Deposited 1997-05-27 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：G61A FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7；60-70% AMMONIUM SULFATE, 100MM TRIS-HCL, pH 7.0
Resolution 1.58 Å
1AKT G61N OXIDIZED FLAVODOXIN MUTANT Deposited 1997-05-27 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：G61N FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7；60-70% AMMONIUM SULFATE, 100MM TRIS-HCL, pH 7.0
Resolution 1.80 Å
1AKU D95A HYDROQUINONE FLAVODOXIN MUTANT FROM D. VULGARIS Deposited 1997-05-27 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：D95A SO4 SULFATE ION × 2 FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7；60-70% AMMONIUM SULFATE, 100MM TRIS-HCL, PH=7.0.
Resolution 1.90 Å R-free 0.270
1AKV D95A SEMIQUINONE FLAVODOXIN MUTANT FROM D. VULGARIS Deposited 1997-05-27 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：D95A SO4 SULFATE ION × 4 FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7；60-70% AMMONIUM SULFATE, 100MM TRIS-HCL, PH=7.0.
Resolution 2.00 Å R-free 0.250
1AKW G61L OXIDIZED FLAVODOXIN MUTANT Deposited 1997-05-27 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：G61L FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7；60-70% AMMONIUM SULFATE, 100MM TRIS-HCL, pH 7.0
Resolution 1.75 Å R-free 0.194
1AZL G61V FLAVODOXIN MUTANT FROM DESULFOVIBRIO VULGARIS Deposited 1997-11-18 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：G61V FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions macroseeding；pH 7；PROTEIN SEED CRYSTALS WERE OBTAINED FROM 60-70% AMMONIUM SULFATE, 10MM TRIS PH 7.0, 1-2% ACETONE. MACROSEEDS WERE TRANSFERRED TO THE ABOVE SOLUTION WITH NO ACETONE PRESENT., macroseeding
Resolution 1.80 Å
1BU5 X-RAY CRYSTAL STRUCTURE OF THE DESULFOVIBRIO VULGARIS (HILDENBOROUGH) APOFLAVODOXIN-RIBOFLAVIN COMPLEX Deposited 1998-09-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain not uniquely mapped Reference range not declared
Chain A 2–148（147 aa）
Not recorded SO4 SULFATE ION × 2 RBF RIBOFLAVIN × 2 X-RAY DIFFRACTION
X-ray crystallization conditions pH 7；CRYSTALS WERE GROWN USING THE HANGING DROP METHOD OF VAPOUR DIFFUSION FROM TRIALS WITH AMMONIUM SULPHATE IN THE CONCENTRATION RANGE 60-80% SATURATION IN 50MM SODIUM PHOSPHATE BUFFER PH 8.0 CONTAINING 1MM EDTA WITH A PROTEIN CONCENTRATION OF 10-15MG/ML. CRYSTALS APPEAR OVER 1-3 DAYS., pH 7.0
Resolution 1.83 Å R-free 0.202
1C7E D95E HYDROQUINONE FLAVODOXIN MUTANT FROM D. VULGARIS Deposited 2000-02-16 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：D95E FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.5；70-73% A.S., 210MM TRIS-HCL, 200MM SODIUM ACETATE PH=8.5
Resolution 2.25 Å R-free 0.297
1C7E D95E HYDROQUINONE FLAVODOXIN MUTANT FROM D. VULGARIS Deposited 2000-02-16 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 2–148（147 aa）
Mutation：D95E FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 8.5；70-73% A.S., 210MM TRIS-HCL, 200MM SODIUM ACETATE PH=8.5
Resolution 2.25 Å R-free 0.297
1C7F D95E OXIDIZED FLAVODOXIN MUTANT FROM D. VULGARIS Deposited 2000-02-11 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：YES FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5；70-70% A.S. 210MM TRIS-HCL PH=6.5, 200MM SODIUM ACETATE
Resolution 2.00 Å R-free 0.240
1C7F D95E OXIDIZED FLAVODOXIN MUTANT FROM D. VULGARIS Deposited 2000-02-11 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain B 2–148（147 aa）
Mutation：YES FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions pH 6.5；70-70% A.S. 210MM TRIS-HCL PH=6.5, 200MM SODIUM ACETATE
Resolution 2.00 Å R-free 0.240
1F4P Y98W FLAVODOXIN MUTANT 1.5A (D. VULGARIS) Deposited 2000-06-08 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：Y98W FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.3；292 K；Ammonium Sulfate, Tris Buffer, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 292.K
Resolution 1.30 Å R-free 0.169
1FX1 A CRYSTALLOGRAPHIC STRUCTURAL STUDY OF THE OXIDATION STATES OF DESULFOVIBRIO VULGARIS FLAVODOXIN Deposited 1984-10-15 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1–148（148 aa）
Not recorded FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 2.00 Å
1I1O ROOM TEMPERATURE CRYSTAL STRUCTURE FLAVODOXIN D. VULGARIS MUTANT Y98H AT 2.0 ANG. RESOLUTION Deposited 2001-02-02 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa） Fragment：MAIN CHAIN
Mutation：Y98H FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.3；293 K；3.2 M Ammonium Sulfate, Tris.buffer, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 293K
Resolution 2.00 Å
1J8Q Low Temperature (100K) Crystal Structure of Flavodoxin D. vulgaris Wild-type at 1.35 Angstrom Resolution Deposited 2001-05-22 Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Not recorded FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；Ammonium Sulphate, Tris HCl Buffer, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 1.35 Å R-free 0.181
1J9E Low Temperature (100K) Crystal Structure of Flavodoxin D. vulgaris S35C Mutant at 1.44 Angstrom Resolution Deposited 2001-05-25 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：S35C FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7；295 K；Ammonium sulphate, tris-HCl buffer, pH 7.00, VAPOR DIFFUSION, HANGING DROP, temperature 295K
Resolution 1.44 Å R-free 0.156
1J9G Low Temperature (100K) Crystal Structure of Flavodoxin D. vulgaris S64C Mutant, monomer oxidised, at 2.4 Angstrom Resolution Deposited 2001-05-25 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：S64C FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；Ammonium Sulphate, Tris HCl Buffer, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 295K
Resolution 2.40 Å R-free 0.247
1WSB Flavodoxin mutant- S64C Deposited 2004-11-05 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1–148（148 aa）
Mutation：S64C FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；298 K；temperature 298K, VAPOR DIFFUSION, SITTING DROP
Resolution 1.80 Å R-free 0.249
1WSW Low Temperature (100K) Crystal Structure Of Flavodoxin Mutant S64C, dimer, semiquinone state Deposited 2004-11-12 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 1–148（148 aa）
Mutation：S64C FMN FLAVIN MONONUCLEOTIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；Ammonium Sulphate, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.69 Å R-free 0.245
1XT6 S35C Flavodoxin Mutant in the semiquinone state Deposited 2004-10-21 Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：S35C FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions sitting drop, vapor diffusion；pH 7；298 K；3.2M ammonium sulfate, pH 7, sitting drop, vapor diffusion, temperature 298K
Resolution 1.80 Å R-free 0.261
1XYV Low Temperature (100K) Crystal Structure Of Flavodoxin Mutant S64C, monomer, semiquinone state Deposited 2004-11-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 1–148（148 aa）
Mutation：S64C FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；Ammonium Sulphate, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.79 Å R-free 0.237
1XYY Low Temperature (100K) Crystal Structure Of Flavodoxin Mutant S64C, homodimer, oxidised state Deposited 2004-11-11 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 1–148（148 aa）
Mutation：S64C FMN FLAVIN MONONUCLEOTIDE × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；Ammonium Sulphate, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 298K
Resolution 1.70 Å R-free 0.253
2FX2 COMPARISON OF THE CRYSTAL STRUCTURES OF A FLAVODOXIN IN ITS THREE OXIDATION STATES AT CRYOGENIC TEMPERATURES Deposited 1991-10-17 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa）
Not recorded FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
3FX2 COMPARISON OF THE CRYSTAL STRUCTURES OF A FLAVODOXIN IN ITS THREE OXIDATION STATES AT CRYOGENIC TEMPERATURES Deposited 1991-10-17 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa）
Not recorded FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
4FX2 COMPARISON OF THE CRYSTAL STRUCTURES OF A FLAVODOXIN IN ITS THREE OXIDATION STATES AT CRYOGENIC TEMPERATURES Deposited 1991-10-17 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa）
Not recorded FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
5FX2 COMPARISON OF THE CRYSTAL STRUCTURES OF A FLAVODOXIN IN ITS THREE OXIDATION STATES AT CRYOGENIC TEMPERATURES Deposited 1991-10-17 Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa）
Not recorded FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION mmCIF provides none of the parsed conditions Resolution 1.90 Å
5TGZ Crystal Structure of the Human Cannabinoid Receptor CB1 Deposited 2016-09-28 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa） Fragment：UNP RESIDUES 99-306,UNP RESIDUES 2-148,UNP RESIDUES 332-414
Mutation：T210A, E273K, T283V,P1002A, Y1098W,R340E ZDG 4-[4-[2-(2,4-dichlorophenyl)-4-methyl-5-(piperidin-1-ylcarbamoyl)pyrazol-3-yl]phenyl]but-3-ynyl nitrate × 1 FMN FLAVIN MONONUCLEOTIDE × 1 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1 OLA OLEIC ACID × 3 PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions LIPIDIC CUBIC PHASE；293 K；0.1M HEPES pH 7.0-7.4, 100mM (NH4)2HPO4, 25%-32% PEG 400, 2-20 mM Ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA)
Resolution 2.80 Å R-free 0.238
5V56 2.9A XFEL structure of the multi-domain human smoothened receptor (with E194M mutation) in complex with TC114 Deposited 2017-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 2–148（147 aa） Fragment：UNP RESIDUES 53-433,444-558
Chain B 2–148（147 aa） Fragment：UNP RESIDUES 53-433,444-558
Mutation：E194E, P2A, Y98W Mutation：E194E, P2A, Y98W 836 N-methyl-N-[1-[4-(2-methylpyrazol-3-yl)phthalazin-1-yl]piperidin-4-yl]-4-nitro-2-(trifluoromethyl)benzamide × 2 FMN FLAVIN MONONUCLEOTIDE × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 X-RAY DIFFRACTION
X-ray crystallization conditions LIPIDIC CUBIC PHASE；293 K；100 mM Sodium citrate tribasic dihydrate pH 5.0, 36% (v/v) PEG400, 50-200 mM Ammonium nitrate
Resolution 2.90 Å R-free 0.239
5V57 3.0A SYN structure of the multi-domain human smoothened receptor in complex with TC114 Deposited 2017-03-13 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric
Chain A 2–148（147 aa） Fragment：UNP RESIDUES 58-433,444-558
Chain B 2–148（147 aa） Fragment：UNP RESIDUES 58-433,444-558
Mutation：P2A, Y98W Mutation：P2A, Y98W 836 N-methyl-N-[1-[4-(2-methylpyrazol-3-yl)phthalazin-1-yl]piperidin-4-yl]-4-nitro-2-(trifluoromethyl)benzamide × 2 FMN FLAVIN MONONUCLEOTIDE × 2 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1 X-RAY DIFFRACTION
X-ray crystallization conditions LIPIDIC CUBIC PHASE；pH 5；293 K；100 mM Sodium citrate tribasic dihydrate pH 5.0, 36% (v/v) PEG 400, 50-200 mM Ammonium nitrate
Resolution 3.00 Å R-free 0.240
5XR8 Crystal structure of the human CB1 in complex with agonist AM841 Deposited 2017-06-07 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa） Fragment：;UNP residues 99-306,UNP residues 3-148,UNP residues 332-414,UNP residues 99-306,UNP residues 3-148,UNP residues 332-414,UNP residues 99-306,UNP residues 3-148,UNP residues 332-414 ;
Mutation：T210A,E273K,T283V,Y1098W,R340E FMN FLAVIN MONONUCLEOTIDE × 1 8D0 (6~{a}~{R},9~{R},10~{a}~{R})-9-(hydroxymethyl)-3-(8-isothiocyanato-2-methyl-octan-2-yl)-6,6-dimethyl-6~{a},7,8,9,10,10~{a}-hexahydrobenzo[c]chromen-1-ol × 1 CLR CHOLESTEROL × 1 PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions LIPIDIC CUBIC PHASE；pH 6.2；293 K；0.1 M sodium cacodylate trihydrate pH 6.2, 120 mM C6H5Na3O7, 30% PEG400 and 100 mM Glycine
Resolution 2.95 Å R-free 0.274
5XRA Crystal structure of the human CB1 in complex with agonist AM11542 Deposited 2017-06-08 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa） Fragment：UNP residues 99-306,UNP residues 3-148,UNP residues 332-414
Mutation：T210A, E273K, T283V,Y1098W,R340E FMN FLAVIN MONONUCLEOTIDE × 1 8D3 (6aR,10aR)-3-(8-bromanyl-2-methyl-octan-2-yl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol × 1 OLA OLEIC ACID × 2 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2 PEG DI(HYDROXYETHYL)ETHER × 1 CLR CHOLESTEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions LIPIDIC CUBIC PHASE；293 K；0.1 M sodium cacodylate trihydrate pH 6.4, 300-350 mM C4H4KNaO6, 30% PEG400
Resolution 2.80 Å R-free 0.252
5YOB Crystal Structure of flavodoxin without engineered disulfide bond Deposited 2017-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa）
Mutation：Y98W FMN FLAVIN MONONUCLEOTIDE × 1 GOL GLYCEROL × 2 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Tris-HCL 0.1M Ammonium Sulfate 3.2M
Resolution 1.14 Å R-free 0.177
5YOC Crystal Structure of flavodoxin with engineered disulfide bond C102-R125C Deposited 2017-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa）
Mutation：R125C, Y98W FMN FLAVIN MONONUCLEOTIDE × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Tris-HCL 0.1M Ammonium Sulfa 3.1M
Resolution 1.50 Å R-free 0.192
5YOE Crystal Structure of flavodoxin with engineered disulfide bond A43C-L74C Deposited 2017-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa）
Mutation：A43C, L74C, Y98W FMN FLAVIN MONONUCLEOTIDE × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；293 K；Tris-HCL 0.1M Ammonium Sulfate 3.2M
Resolution 1.35 Å R-free 0.181
5YOG Crystal Structure of flavodoxin with engineered disulfide bond N14C-C93 Deposited 2017-10-27 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa）
Mutation：N14C, Y98W FMN FLAVIN MONONUCLEOTIDE × 1 GOL GLYCEROL × 2 SO4 SULFATE ION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP；pH 7.3；293 K；Tris-HCL buffer, pH 7.3 Ammonium Sulfate 3.1M
Resolution 1.42 Å R-free 0.180
5ZKP Crystal structure of the human platelet-activating factor receptor in complex with SR 27417 Deposited 2018-03-25 Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 2–148（147 aa）
Mutation：F116Y, N169D,P2A, Y98W,A230D, V234A, D289N 9ER N1,N1-dimethyl-N2-[(pyridin-3-yl)methyl]-N2-{4-[2,4,6-tri(propan-2-yl)phenyl]-1,3-thiazol-2-yl}ethane-1,2-diamine × 1 FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions LIPIDIC CUBIC PHASE；293 K；HEPES, PEG 400, NaSCN, Na citrate
Resolution 2.81 Å R-free 0.259
6LI0 Crystal structure of GPR52 in complex with agonist c17 Deposited 2019-12-10 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa）
Mutation：A130W,Y1098W,A264L,W278Q,C314P,S318A,N321D,V323T EN6 N-(2-hydroxyethyl)-5-(hydroxymethyl)-3-methyl-1-[2-[[3-(trifluoromethyl)phenyl]methyl]-1-benzothiophen-7-yl]pyrazole-4-carboxamide × 1 FMN FLAVIN MONONUCLEOTIDE × 1 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 17 PEG DI(HYDROXYETHYL)ETHER × 8 FLC CITRATE ANION × 1 X-RAY DIFFRACTION
X-ray crystallization conditions LIPIDIC CUBIC PHASE；pH 5；293 K；0.13-0.18 M sodium acetate, 0.1 M sodium citrate PH5.0, 32-35% PEG400
Resolution 2.20 Å R-free 0.220
6LI1 Crystal structure of GPR52 ligand free form with flavodoxin fusion Deposited 2019-12-10 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa）
Mutation：A130W,Y1098W,W278Q,C314P,S318A,N321D,V323T OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2 FMN FLAVIN MONONUCLEOTIDE × 1 PEG DI(HYDROXYETHYL)ETHER × 1 PGE TRIETHYLENE GLYCOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions LIPIDIC CUBIC PHASE；pH 5；293 K；0.1 M potassium acetate, 0.1 M sodium citrate pH 5.0, and 30% PEG400
Resolution 2.90 Å R-free 0.267
7DDZ The Crystal Structure of Human Neuropeptide Y Y2 Receptor with JNJ-31020028 Deposited 2020-10-30 Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa）
Not recorded H46 ~{N}-[4-[4-[(1~{S})-2-(diethylamino)-2-oxidanylidene-1-phenyl-ethyl]piperazin-1-yl]-3-fluoranyl-phenyl]-2-pyridin-3-yl-benzamide × 1 FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions LIPIDIC CUBIC PHASE；293.15 K；0.1 M HEPES, pH 7.0-7.5, 250-350 mM (NH4)2SO4, and 20-30% PEG500DME, or 0.1 M MES, pH 6.0-6.5, 380-420 mM NH4 tartrate, and 24-26% PEG500DME
Resolution 2.80 Å R-free 0.289
7V3Z Structure of cannabinoid receptor type 1(CB1) Deposited 2021-08-12 Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric
Chain A 3–148（146 aa）
Mutation：H154L,T210A,E273K,T283V,Y1098W,R340E 9GF 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol × 1 CLR CHOLESTEROL × 1 FMN FLAVIN MONONUCLEOTIDE × 1 X-RAY DIFFRACTION
X-ray crystallization conditions LIPIDIC CUBIC PHASE；pH 7.2；293.15 K；30% PEG400, 100 mM HEPES sodium pH 7.2, 80-100mM sodium citrate tribasic dihydrate
Resolution 3.29 Å R-free 0.276

39 other PDB entries and 41 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name FLAV_DESVH
Isoform —
PDB entities 1
Chains and sequence ranges Author chain A； PDBConstruct 236–382； UniProt 2–148

Leukotriene B4 receptor 1,Flavodoxin,Leukotriene B4 receptor 1

Homo sapiens

UniProt Q15722

State in the Current Structure

Assembly Oligomeric State Construct Mutations and Modifications Ligands, Ions and Associated Components Method and Experimental Conditions Structure Quality
1 Insufficient information Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count Chain A； UniProt 5–212 Chain A； UniProt 213–310 Not recorded VRJ N-(tert-butylsulfonyl)-4-fluoro-2-{(3S,4R)-4-hydroxy-3-[(pyridin-2-yl)methyl]-3,4-dihydro-2H-1-benzopyran-7-yl}benzamide × 1 NA SODIUM ION × 1 FMN FLAVIN MONONUCLEOTIDE × 1 OLA OLEIC ACID × 1 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2 1PE PENTAETHYLENE GLYCOL × 1 2PE NONAETHYLENE GLYCOL × 1 P6G HEXAETHYLENE GLYCOL × 1 X-RAY DIFFRACTION X-ray crystallization conditions：LIPIDIC CUBIC PHASE；pH 5.8；293 K；sodium citrate tribasic dihydrate pH 5.8, sodium acetate trihydrate, benzamidine hydrochloride, PEG-400, MK-D-046, DMSO Resolution 2.88 Å R-free 0.261

Other States of the Same Protein in the Database

Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.

Other PDB Difference from Current Entry 7K15 Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Method and Experimental Conditions Structure Quality
7VKT cryo-EM structure of LTB4-bound BLT1 in complex with Gi protein Deposited 2021-10-01 Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric
Chain A 1–352（352 aa）
Mutation：L106W/A196I/C287F/S310A LTB LEUKOTRIENE B4 × 1 Y01 CHOLESTEROL HEMISUCCINATE × 4 8IO [(2R)-2-[(Z)-hexadec-9-enoyl]oxy-3-[oxidanyl-[(2S,3R,5R,6S)-2,3,4,5,6-pentakis(oxidanyl)cyclohexyl]oxy-phosphoryl]oxy-propyl] octadecanoate × 1 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.90 Å

1 other PDB entries and 1 assemblies. Open the comparison page and filter oligomeric states

View Construct and Data Evidence
UniProt name LT4R1_HUMAN
Isoform —
PDB entities 1
Chains and sequence ranges Author chain A； PDBConstruct 28–235； UniProt 5–212 Author chain A； PDBConstruct 385–482； UniProt 213–310

The page prioritizes protein identity, the current assembly, associated components, oligomeric state and cross-PDB links. Chain mapping and sequence ranges are retained as data evidence. Internal IDs, import timestamps and assembly operation expressions are maintenance fields and are not shown here.

SAXS scattering curve SAXS Profile

SAXS profile for 7k15

P(r) Distance Distribution P(r) Distribution

P(r) distribution for 7k15
Download Download
▼

2. Structure Basics 2. Structure Basics

Entry ID entry_id7k15
Deposition date deposition_date2020-09-07
Structure title titleCrystal structure of the Human Leukotriene B4 Receptor 1 in Complex with Selective Antagonist MK-D-046
Keywords keywords;Human Leukotriene B4 Receptor 1, hBLT1, BLT1, BLTR1, LTB4, LTB4R, LT4R1, LTB4R1, MK-D-046, selective antagonist, inflammation, inflammatory disease, Type 2 Diabetes, G protein-coupled receptor, GPCR, flavodoxin fusion, membrane protein, LCP ;; MEMBRANE PROTEIN
Experimental Method methodX-RAY DIFFRACTION
▼

3. SAXS Parameters (CRYSOL theoretical calculation) 3. SAXS Parameters (CRYSOL)

Radius of gyration Rg (Guinier) rg_guinier33.95 Å
Radius of gyration Rg (electron density) rg_electron33.18 Å
Forward intensity I(0) i036901800.00
Molecular weight molecular_weight51213.0 kDa
Excluded volume excluded_volume65437 ų
Envelope volume envelope_volume83254 ų
Hydration-shell volume shell_volume22824 ų
Envelope diameter envelope_diameter120.5 Å
Shell Rg shell_rg36.51 Å
Envelope Rg envelope_rg32.66 Å
Shape Rg shape_rg33.23 Å
Total Rg total_rg33.30 Å
Total atoms total_atoms3611
Residues n_residues455
Spherical-harmonic order n_harmonics20
q range q_range— – 0.5000 Å−1
Data points n_points101
Shell type shell_typedirectional
Solvent electron density solvent_density0.3340 e/ų
Shell contrast contrast_shell0.0300 e/ų
CRYSOL version crysol_version4.1.3
▼

4. P(r) Distance Distribution (GNOM inversion) 4. P(r) Analysis (GNOM)

Maximum dimension Dmax dmax112.8 Å
Rg (real space) rg_real34.28 Å
Rg uncertainty (real space) rg_real_error1.20 Å
I(0) (real space) i0_real3.6900e+07
I(0) uncertainty (real space) i0_real_error6.7370e+05
Rg (reciprocal space) rg_reciprocal34.08 Å
I(0) (reciprocal space) i0_reciprocal36900000.0000
Solution quality estimate total_estimate0.7297
Solution quality rating solution_quality REASONABLE a REASONABLE solution
P(r) peaks n_peaks3
Primary peak position r_peak_primary21.6 Å
Skewness Skewness skewness0.391
Kurtosis Kurtosis kurtosis-0.819
Angular range angular_range— – 0.2350 Å−1
Current regularization parameter α current_alpha0.0000
Highest regularization parameter α highest_alpha5964000.0000
Real-space data points n_real_points48
GNOM version gnom_version4.1.3
Quality Criteria quality_criteria AN1: 0.000; Oscil: 0.459; Stabil: 1.000; Sysdev: 1.000; Positv: 1.000; Valcen: 0.230; Smooth: 0.874
▶

5. Crystallography and Experiment 5. Crystallography & Experiment

▶

6. Entities and Polymers Entities & Polymers (10)

▶

8. Citations (1)

▶

9. Files and Curves (10)